Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27016231 | 0.97 | NR3C1 (0.37) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL27016238 | 0.97 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL26057457 | 0.96 | NR3C1 (0.41) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL23464421 | 0.94 | ALDH1A1 (0.43) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL26057456 | 0.94 | NR3C1 (0.38) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL27016237 | 0.94 | ALDH1A1 (0.38) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL26054735 | 0.94 | NR3C1 (0.40) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL26054552 | 0.93 | NR3C1 (0.41) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL20155956 | 0.92 | NR3C1 (0.46) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL26057455 | 0.92 | CYP1A2 (0.39) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018127-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018127-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018127-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | OR10J3, ORC3, ORAI3 | ALDH1A1 1566/4885LMNA 3414/4885HPGD 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.